Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Nanalysis Scientific Corp. (NSCIF)
Calgary, AB, CA
Nanalysis Scientific Corp. develops, manufactures, and sells magnetic resonance technology products in Canada, the United States, Europe, Asia, and internationally. The company operates through Scientific Equipment and Security Services segment. It offers nuclear magnetic resonance (NMR) spectrometers; magnetic resonance test, and measurement and diagnostic system; 60-NMR platform; 100-NMR platform; 60-TEACH Platform; QUAD NMR Console; and Cameleon 4 console, a compact alternative to facilitate MRI for teaching. The company also provides software products, such as NMRGui, an user interface for data acquisition and processing of benchtop NMR product; SPINit MR software platform to facilitate data acquisition, processing, and pulse programming; and NMRFx platform that offers a suite of software tools to streamline and automate MR data analysis and management. In addition, it offers security service, including preventive and on-call maintenance services, scheduled preventative maintenance work, corrective maintenance work, installation and upgrade projects for detection and general security equipment; other technical maintenance services; and installation and maintenance services for commercial security equipment, such as scanning devices, metal detectors, detection equipment, and other general security equipment. It serves pharmaceutical, biotechnology, nutraceutical, chemical, security, food, oil and gas, materials, life science, medical, and educational industries. The company is headquartered in Calgary, Canada.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -2.86% | -3.59% | -5.47% | -15.00% | -8.85% | -50.24% | -76.58% | -74.93% | -73.61% | -73.61% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Medical - Specialties: +8.3%-11.8% Q1'26: +0.9% (vs Q1'25)
-
EPS growth Medical - Specialties: +10.1%+58.3% ★ Q1'26: +5.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Specialties: +51.3%-1.0% Q1'26: -3.2% (vs Q1'25)
-
EBIT margin Medical - Specialties: +12.6%-10.7% Q1'26: -8.2% (vs Q1'25)
-
ROIC Medical - Specialties: +6.6%-14.0% Q1'26: -12.9% (vs Q1'25)
-
Share dilution Medical - Specialties: 0.0%+3.7% Q1'26: +20.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Specialties: -0.39×-20.80× Q1'26: 285.96× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
16.04M
est: 16.12M (-0.5%)
|
24.82M
est: 24.28M (+2.2%)
|
28.47M
est: 28.10M (+1.3%)
|
45.50M
est: 44.17M (+3.0%)
|
40.13M
est: 41.23M (-2.7%)
|
42.14M
42.14M – 42.14M
+2.2% YoY
|
45.06M
45.06M – 45.06M
+6.9% YoY
|
48.22M
48.22M – 48.22M
+7.0% YoY
|
| EBITDA |
1.38M
est: -2.72M (+150.5%)
|
-5.26M
est: -4.10M (-28.2%)
|
-8.85M
est: -4.75M (-86.3%)
|
-7.66M
est: -5.53M (-38.5%)
|
-845.0K
est: -5.17M (+83.6%)
|
-5.28M
-5.28M – -5.28M
-2.2% YoY
|
-5.65M
-5.65M – -5.65M
-6.9% YoY
|
-6.04M
-6.04M – -6.04M
-7.0% YoY
|
| EBIT |
-1.19M
est: -5.42M (+78.0%)
|
-9.91M
est: -8.16M (-21.5%)
|
-13.51M
est: -9.44M (-43.1%)
|
-12.29M
est: -11.70M (-5.0%)
|
-4.27M
est: -10.92M (+60.9%)
|
-11.17M
-11.17M – -11.17M
-2.2% YoY
|
-11.94M
-11.94M – -11.94M
-6.9% YoY
|
-12.78M
-12.78M – -12.78M
-7.0% YoY
|
| Net Income |
-1.77M
est: -2.23M (+20.5%)
|
-9.92M
est: -9.87M (-0.5%)
|
-16.78M
est: -18.81M (+10.8%)
|
-13.61M
est: -6.88M (-97.9%)
|
-5.66M
est: -5.16M (-9.7%)
|
1.04M
1.04M – 1.04M
+120.3% YoY
|
3.95M
3.95M – 3.95M
+277.8% YoY
|
4.99M
4.99M – 4.99M
+26.5% YoY
|
| SGA |
8.28M
est: 8.45M (-2.0%)
|
14.35M
est: 12.73M (+12.7%)
|
12.39M
est: 14.74M (-15.9%)
|
11.29M
est: 17.93M (-37.0%)
|
10.11M
est: 16.74M (-39.6%)
|
17.11M
17.11M – 17.11M
+2.2% YoY
|
18.30M
18.30M – 18.30M
+6.9% YoY
|
19.58M
19.58M – 19.58M
+7.0% YoY
|
| EPS |
-0.03
est: -0.02 (-65.7%)
|
-0.11
est: -0.09 (-23.3%)
|
-0.16
est: -0.17 (+5.9%)
|
-0.12
est: -0.06 (-100.1%)
|
-0.05
est: -0.04 (-11.2%)
|
0.01
0.01 – 0.01
+120.3% YoY
|
0.03
0.03 – 0.03
+277.8% YoY
|
0.04
0.04 – 0.04
+26.5% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Sean Krakiwsky | Founder, Chief Executive Officer, President & Director | 220.8K | male |
| Marc Tomlinson | Executive Vice President of Services | 167.4K | male |
| Julien Mueller | Chief Technology Officer | 147.8K | male |
| Martin Andrew Burian | Corporate Secretary & Independent Chairman | 23.9K | male |
| Heather Kury | Interim CFO & Corporate Controller | — | female |
| Susanne Riegel | Vice President of Marketing & Product Manager | — | — |
| Matthew Selinger | Investor Relations Manager | — | male |
| Neal Gallagher | VP of Engineering & Operations | — | male |
| Robert Borkowsky | Executive Officer | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for NSCIF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
